Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, summarizes three abstracts for which she was the discussant. The topics were rates of surgical site infections, an online resource for hospital cancer surgery volumes, and barriers to oncology appointments at comprehensive cancer centers. (Abstracts 171, 172, 55)
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Joseph V. Simone, MD, of the Simone Consulting Company, reflects on the prospects for the future of safety and quality.
Dawn L. Hershman, MD, of Columbia University Medical Center, summarizes a joint ASCO/NCI session on this important topic, including the challenges and solutions.
Joseph O. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses a session he co-chaired on the thorny questions of how best to improve cancer care.
